ERBB3 and ovarian cancer: More recently, Matulonis and colleagues demonstrated that tumor HER3 expression is a better predictor than HER2 for response to pertuzumab (a HER2-directed therapeutic antibody) in patients with platinum-resistant ovarian cancer [32].